CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025, ending June 30. The company recorded revenues of $4.2 million, showing a 5% increase from $4.0 million in the same period last year. The cost of revenue also rose to $2.1 million, an 11% increase from last year's $1.9 million. The company's net loss for the quarter was $13.4 million, compared to a net loss of $7.0 million in the same quarter of the prior year. A significant portion of this loss includes a $2.2 million investment loss related to Precision Autoimmune Therapeutics. Research and development expenses increased by 31% to $1.7 million, primarily driven by the development of CID-103. General and administrative expenses remained stable at $6.1 million, while selling and marketing expenses rose by 14% to $5.0 million, attributed to heightened marketing efforts due to increased competition from local melphalan generic products. CASI Pharmaceuticals continues to focus on advancing CID-103 and aims to deliver long-term value for its stakeholders by concentrating on organ transplant rejection and autoimmune indications. The company held cash and cash equivalents totaling $6.7 million as of June 30, 2025, down from $13.5 million at the end of 2024.